Biologic and Mechanical Mitral Valve Prostheses: Outcomes in 50- to 69-Year-Olds

Mechanical prostheses are associated with more bleeding and stroke but with less reoperation risk.

Patients undergoing mitral valve replacement (MVR) need to balance the long-term risk of structural deterioration of biologic prostheses with the anticoagulation risks of mechanical ones. In this retrospective cohort study, investigators utilized a New York State database to examine outcomes in 3433 patients aged 50 to 69 who had MVR between 1997 and 2007.

The 2638 patients with mechanical prostheses (77%) tended to be younger and to have fewer comorbidities than bioprostheses recipients. Propensity scoring on age and comorbidities was used to identify 664 pairs of patients (mechanical prosthesis in one, biologic prosthesis in the other); 30-day mortality in the prosthesis groups was similar (about 5%). They were followed for a median of 8 y…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)